The capsid license follows an agreement between Dyno and Roche originally announced in May 2020 and marks Dyno’s first adeno-associated virus (AAV) capsid licensing and partnership completion.

Apart from the main CQAs mentioned above (capsid content ... Guidance Manual provides good separation of monomers, aggregates and fragments for different AAV serotypes. Wyatt’s AAV SEC-MALS ...

Two fundamental aspects of AAV research are the accurate quantification of AAV capsid titters and the detection of pre-existing antibodies against AAV. These measurements are essential for ensuring ...

One capsid, AAV-KP1, stood out as particularly effective when administered directly to the kidneys via the renal vein or pelvis, reaching kidney cells with minimal impact on the liver. In contrast ...

RICHMOND, Calif., December 30, 2024--SANGAMO THERAPEUTICS TO REGAIN FULL RIGHTS TO HEMOPHILIA A GENE THERAPY PROGRAM FOLLOWING PFIZER’S DECISION TO CEASE DEVELOPMENT Astellas Pharma Inc.

Increase in global defense spending due to heightened geopolitical tensions and the spread of regional conflicts is a primary factor contributing to the bismaleimide monomer market growth. Governments ...

The capsid license is pursuant to the agreement ... While naturally occurring AAV capsids lack precise targeting to deliver medicine to the right cells, are difficult to manufacture, and have ...